semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Type 2 Diabetes Mellitus Diabetic Nephropathy Patients with type 2 diabetes 2. Urinary albumin-to-creatinine ratio: >=300 mg/g creatinine twice in the first morning urine sample 3. Serum creatinine level: =<2.5 mg/dl 4. Patients aged 20-75 years  Type 1 diabetes 2. Hereditary diabetes or secondary diabetes 3. Non-diabetic nephropathy 4. Familial hypercholesterolemia 5. Secondary hypertension 6. Unstable angina pectoris or history of myocardial infarction/stroke within 6 months prior to consent acquisition 7. Malignant tumor or life threatening disease 8. History of angioedema 9. Patients undergoing LDL apheresis 10. Biliary system obstruction or severe liver injury 11. Liver dysfunction 12. Allergy for ACE-Is, ARBs or HMG-CoA reductase inhibitors 13. Pregnant or nursing patients 14. Others: patients who are not suitable for this trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Shortness of Breath Acute Exacerbation Acute shortness of breath of unknown etiology as presentation to the emergency room 2. Possible acute exacerbation of known heart failure  None -
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes Informed consent obtained before any trial-related activities. 2. Diagnosed type 1 diabetes before the age of 40 and on insulin treatment within one year of diagnosis. 3. Insulin treatment of any regime for more than one year at time of inclusion. 4. Total insulin demand ≥ 0,5 IU/kg/24 hrs 5. HbA1c between 7% and 12 % (both values included). 6. Age ≥ 18 years. 7. BMI between 18 and 35 kg /m2 (including both values)  Known or suspected allergy to trial product(s) or related products. 2. Recurrent major hypoglycaemic episodes. 3. Heart: Unstable Angina Pectoris, AMI < 12 months or heart insufficiency classified according to NYHA III-IV 4. Blood Pressure: Severe uncontrolled hypertension with BP > 180/110 mmHg, sitting 5. Liver: Impaired hepatic function corresponding to serum-ALAT or -basic phosphatase > 2x upper reference limit of the local laboratory. 6. Kidneys: Impaired renal function corresponding to serum-creatinin > 150 μmol/l according to the local laboratory. 7. Any disease judged by the investigator to affect the trial. 8. Pregnancy, breast feeding or the intention of becoming pregnant or fertile women not using adequate contraceptive measures adequate contraceptive method is sterilisation, hysterectomy or current use of contraceptive pills or intra uterine device. 9. The receipt of any investigational drug within a three month period prior to this trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-73.0,  Coronary Heart Disease male gender 2. age 73 or younger 3. presence of CHD 4. HDL-C le 40 mg/dl 5. LDL-C le 140 mg/dl 6. triglycerides le 300 mg/dl  significant medical illness 2. alcohol or substance abuse 3. evidence of cholecystitis or cholelithiasis 4. ejection fraction of lt 35% 5. current use of steroids, estrogens, immunosuppressive agents, oral coagulants, or lipid modifying drug. 6. allergic to gemfibrozil or fibric acid 7. refused informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Mixed Hyperlipidemia Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL  Pregnant or lactating women, or women intending to become pregnant Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin) Human immunodeficiency virus (HIV) positive Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty Active or chronic liver disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diastolic Heart Failure Patients must meet all of the following to be eligible for enrollment into the study: 1. Male or non-pregnant female (if female, either post-menopausal, or if of child-bearing potential, using adequate contraception e.g. hormonal or barrier methods, or surgically sterile, and not lactating) 2. Age >/= 18 years of age 3. Present or prior history of symptoms of heart failure (dyspnea, fatigue) consistent with diagnosis of diastolic heart failure, following optimized medical therapy including blood pressure control with ACE inhibitors and/or beta-blockers for 2 weeks or over. 4. Echocardiographic evidence of preserved left ventricular systolic function (LVEF >/= 45%) and evidence of diastolic dysfunction (by transmitral inflow, pulmonary venous flow, color M-mode and/or tissue Doppler). 5. Signed informed consent  The presence of any of the following will a patient from study enrollment: 1. Unwilling to participate for the 9-month duration of the study 2. Significant primary valvular, pulmonary or congenital cardiac disease believed to be the cause of dyspnea 3. Life expectancy or planned cardiac transplantation <9 months 4. History of hypertrophic obstructive cardiomyopathy 5. Unstable angina or ischemia requiring revascularization 6. Renal insufficiency (Cr >2.0 mg/dL in males and >1.8 mg/dl in females, or modified Cockcroft-Gault estimate of creatinine clearance <30 mL/min) at enrollment 7. Known hypersensitivity to spironolactone or eplerenone 8. Decompensated heart failure or clinical evidence of instability at the time of enrollment 9 History of hyperkalemia (>6.0 mg/dL) with spironolactone 10. Use of spironolactone or amiloride within 30 days 11. Poorly controlled seating blood pressure at the time of drug initiation Systolic blood pressure >160 mmHg; and/or Diastolic blood pressure >100 mmHg
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Type 1 Diabetes Mellitus Ages 18 to 50 years old Body mass index (BMI) 20 to 27 kg/m2 and a total body weight > 50 kg (110 lbs) Blood pressure: systolic < 150; diastolic < 95 Type 1 DM Have diagnosed diabetes type 1 for a minimum of 12 months prior to study entry In good general health with no evidence or history of clinically significant hematological, renal, endocrine (other than diabetes), pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) Hematocrit (Hct) > 34% ALT < 60; AST < 60 Alkaline phosphatase (Alk Phos) < 150 Sensitive thyroid-stimulating hormone (sTSH) < 6  if unable to master use of the inhalation device after 3 attempts if positive urine drug screen if any episodes of severe hypoglycemia in the past 3 months if pregnant or breastfeeding or unwilling to use an acceptable method of non-hormonal contraception from at least 14 days prior to the first dose of Exubera® until study is completed if any history of (h/o) asthma or chronic obstructive pulmonary disease (COPD) if forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) < 70% predicted if treatment with an investigational drug within 30 days preceding the first dose of trial medication if blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing if unable or unwilling to comply with the protocol as written if any use of tobacco or nicotine containing products within the past 6 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Kidney Failure, Acute Critical Illness Age > 18 yrs ICU stay > 48 hours  Age < 18 yrs Creatinine > 180 µmol/L Absence of consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Kidney Failure Scheduled for Angiography in >= 24hrs from enrolment Documented Cr >= 150 within 3 months before cardiac catheterization AND/OR documented Cr >= 132umol/L within 1 week Before Cardiac Catheterization Currently Taking an ACE Inhibitor  Patients with end stage renal disease (for example, patient on dialysis) Emergency Cardiac Catheterization with insufficient time to hold the ACEI Acute Pulmonary Edema
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-100.0,  Atherosclerosis Any adult patient with carotid artery disease or known atherosclerosis capable of giving informed consent. FOR Any adult with normal total cholesterol (less than 200 mg/dl) and blood pressure (systolic less than 140 and diastolic less than 90). FOR Any healthy adult subject with no history of peripheral or coronary artery disease, who is eligible for bronchoalveolar lavage per Protocol 99-H-0068 and capable of giving informed consent  Unable to give consent History of chronic infections, vasculitis or any other inflammatory disease History of neoplastic disease or chemotherapy treatment Immunosuppressive medications other than common over-the-counter drugs such as aspirin or acetaminophen FOR Subject with abnormal liver and renal function tests on pretreatment screening or currently taking a statin or ACE inhibitor medication FOR Any for normal subject listed in Protocol 99-H-0068
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 2.0-100.0,  Hypercholesterolemia Atherosclerosis The following is a representative list of the types of patient presentations and potential diagnoses eligible for this protocol: 1. Plasma cholesterol levels greater than 200 mg/dl or less than 120 mg/dl includes patients with diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia, sitosterolemia, lipoprotein lipase, hepatic lipase or apo-CII deficiency, and dysbetalipoproteinemia. <TAB> 2. Plasma LDL-C levels greater than 130 mg/dl or less than 70 mg/dl includes patients with diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia, lipoprotein lipase, hepatic lipase or apo-CII deficiency, sitosterolemia, dysbetalipoproteinemia, abetalipoproteinemia and hypobetalipoproteinemia. <TAB> 3. Plasma HDL-C levels greater than 70 mg/dl or less than 25 mg/dl includes patients with deficiency of cholesteryl ester transfer protein, lecithin cholesterol acyltransferase, phospholipid transfer protein, lipoprotein lipase, hepatic lipase, or apo-CII, and Tangier disease. <TAB> 4. Plasma triglyceride levels greater than 150 mg/dl includes patients with deficiency of lipoprotein lipase, hepatic lipase or apoC-II, dysbetalipoproteinemia, Type IV and Type V hyperlipidemia  Inability to provide informed consent. In order for cognitively impaired individuals to participate in this protocol, consent will be obtained from the patient's legal guardian. Participating in this protocol will benefit this population of patients since it will facilitate the accurate diagnosis and treatment of their dyslipidemia. Since all of the procedures and assays listed in this protocol are not of an experimental nature, but represent standard of care in tertiary referral hospitals, no further protections need to be in place. 2. Prisoners or other institutionalized persons will be not be allowed to participate because of the possible need for prolonged stay in the Clinical Center. 3. Children less than 2 years of age
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Congestive Heart Failure Clinical diagnosis of heart failure based on a slight modification of the Framingham as previously described within 6 months before the entry Current status of heart failure is NYHA II or III Currently, loop diuretic(s) is (are) administered No change in baseline therapy and symptoms of heart failure within a month  Current symptomatic hypotension Hypertension that has not been controlled to the satisfaction of the investigator Hemodynamically significant (in the investigators opinion) LV outflow tract obstruction (due to either aortic stenosis or ventricular hypertrophy) Acute coronary syndrome Primary pulmonary hypertension or pulmonary hypertension not due to LV dysfunction Serious cerebrovascular disease Acute myocardial infarction within the last 3 months Patients who require intravenous inotropes Cerebrovascular accident within the last 3 months Percutaneous coronary intervention or open heart surgery within the last 3 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Heart Failure, Congestive New York Heart Association (NYHA) class I and II heart failure Chronic ACE-inhibitor treatment  Aspirin treatment in the previous 2 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Diabetes Mellitus, Type I Type 1 diabetes mellitus
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 10.0-21.0,  Congenital Diseases Complete Heart Block Pacemaker between 10 and 21 years of age structurally normal heart congenital complete heart block dual chamber pacemaker, right ventricular apex paced normal function via traditional transthoracic echocardiography  preexisting condition that precludes patient from exercise no informed consent